Lucid Diagnostics Surpasses Q4 2025 Targets, Secures VA Contract for Esoguard
Lucid Diagnostics, a leading diagnostics company, has announced impressive results in its fourth quarter business update conference call. The company's EsoGuard test volume exceeded target ranges, with 3,664 tests conducted in Q4 2025, representing a 29% increase from the third quarter of 2025.
Revenue for the same period came in at $1.5 million, a 24% increase from the previous quarter. This growth is attributed to the company's commercial efforts, including transitioning its team to target both Medicare and the VA, as well as engaging in event-based testing to maintain volume.
A significant milestone was achieved with Lucid Diagnostics being awarded a U.S. Department of Veterans Affairs (VA) contract for EsoGuard. This was issued under the VA Federal Supply Schedule, which centralizes ordering and includes pricing aligned with the established Medicare rate of $1,938.
The VA serves approximately 9 million enrolled veterans annually and operates numerous medical centers across the country. The company believes a significant portion of these patients will be recommended for esophageal precancer testing due to their higher risk factors. Securing this contract at the Medicare rate is seen as a testament to the strength of Lucid Diagnostics' clinical evidence.
The VA's approval process is similar to that of Medicare, and the company expects significant business implications from this development. Lucid Diagnostics will discuss the commercial rollout and business impact in more detail in the coming days.
Additionally, the company announced positive data from a real-world experience study on esophageal precancer testing. The manuscript, which is currently being peer-reviewed for publication, evaluated EsoGuard and EsoCheck in nearly 12,000 at-risk patients. The results showed excellent technical performance, rapid cell collection times, and appropriate physician use across the board.
Dr. Lishan Aklog, Chairman and CEO of Lucid Diagnostics, expressed excitement about these developments during the conference call. "We're entering in 2026 with significant momentum as we await Medicare coverage," he stated, highlighting the company's progress in commercializing its EsoGuard test.
The company's achievements in Q4 2025 demonstrate its commitment to expanding access to diagnostic testing and improving patient outcomes. With its strong clinical evidence and growing commercial presence, Lucid Diagnostics is poised for continued growth and success in 2026 and beyond."
